2.46
+7.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alector
From its filings with the US Securities and Exchange Commission
Alector is based in South San Francisco, California. Its shares trade on Nasdaq under the ticker ALEC. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $21.0m and a net loss of $142.9m. At that date it held total assets of $293.2m and shareholders' equity of $30.6m.
We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption.
Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. We are advancing a portfolio of programs focused on genetically validated targets, supported by our expertise in drug development, protein engineering, and antibody discovery.
A key component of our strategy is the development and application of our Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) delivery technology designed to improve central nervous system exposure across multiple therapeutic modalities. We continue to refine and expand this platform to enable effective brain delivery at clinically practical doses of antibodies, enzymes, and siRNA therapeutics. In parallel, we are investing in biomarkers and biomarker assays to guide patient selection, demonstrate target and pathway engagement, and assess biological impact in the clinic, with the goal of improving development efficiency and the likelihood of technical success.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Feb 2019
- Employees
- 103
- Website
- alector.com ↗
- Head office
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Louis LavigneIndependent Chairman of the Board$257,000
- Dr. Saraswati Kenkare-MitraPresident, Head - Research and Development$2.5m
- Dr. Arnon RosenthalChief Executive Officer, Co-Founder, Director, since 2013$3.7m
- Mr. Neil BerkleyChief Business Officer, Interim Chief Financial Officer
- Mr. Giacomo SalvadoreChief Medical Officer
- Dr. Richard SchellerDirector$403,177
- Mr. Mark AltmeyerIndependent Director$389,093
- Dr. Errol De SouzaIndependent Director$391,051
- Dr. Elizabeth GarofaloIndependent Director$224,500
- Dr. Paula HammondIndependent Director$222,000
- Dr. Kristine YaffeIndependent Director$219,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 70
- Environment
- 73
- Social
- 89
- Governance
- 48
- Women in the workforce
- 62%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alector Inc possess several strengths that contribute to its success:
Weaknesses
- Despite its strengths, Alector Inc also has some weaknesses that need to be addressed:
Opportunities
- Alector Inc can leverage the following opportunities to further grow and expand:
Threats
- Despite the opportunities, Alector Inc must be mindful of the following threats:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.